The Clinical Spectrum and Outcome of Uveomeningitis: A Comprehensive Analysis of 110 Cases

References

• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500. discussion 500. doi:10.1016/j.ophtha.2003.06.014.
   PubMed Web of Science ®Google Scholar
• Rim TH, Kim SS, Ham D-I, et al. Incidence and prevalence of uveitis in South Korea: a nationwide cohort study. Br J Ophthalmol. 2018;102(1):79–83.doi:10.1136/bjophthalmol-2016-309829.
   PubMed Web of Science ®Google Scholar
• Barisani-Asenbauer T, Maca SM, Mejdoubi L, Emminger W, Machold K, Auer H. Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis. 2012;7:57. doi:10.1186/1750-1172-7-57.
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844–848. doi:10.1136/bjo.80.9.844.
   PubMed Web of Science ®Google Scholar
• Brazis PW, Stewart M, Lee AG. The uveo-meningeal syndromes. Neurologist. 2004;10(4):171–184. doi:10.1097/01.nrl.0000131145.26326.ff.
   PubMed Web of Science ®Google Scholar
• Abad S, Terrada C, Trad S, et al. Management of uveomeningitis in internal medicine: proposal for a diagnostic work-up. Rev Med Interne. 2016;37(1):25–34.doi:10.1016/j.revmed.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Hoogewoud F, Frumholtz L, Loubet P, et al. Prognostic factors in syphilitic uveitis. Ophthalmology. 2017;124(12):1808–1816.doi:10.1016/j.ophtha.2017.06.003.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Silpa-Archa N, Preble JM, Foster CS. Vogt-Koyanagi-Harada syndrome: perspectives for immunogenetics, multimodal imaging, and therapeutic options. Autoimmun Rev. 2016;15(8):809–819. doi:10.1016/j.autrev.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Kodjikian L, Broussolle C, Sève P. Sarcoidosis and uveitis. Autoimmun Rev. 2014;13(8):840–849. doi:10.1016/j.autrev.2014.04.001.
   PubMed Web of Science ®Google Scholar
• Noel N, Bernard R, Wechsler B, et al. Long-term outcome of neuro-Behçet’s disease. Arthritis Rheumatol (Hoboken, NJ). 2014;66(5):1306–1314.doi:10.1002/art.38351.
   PubMed Web of Science ®Google Scholar
• Alghamdi A, Bodaghi B, Comarmond C, et al. Neuro-ophthalmological manifestations of Behçet’s disease. Br J Ophthalmol. 2019;103(1):83–87.doi:10.1136/bjophthalmol-2017-311334.
   PubMed Web of Science ®Google Scholar
• Lim LL, Silva DG, Lo TC, Pimentel RS, Butzkueven H, Hall AJ. Uveitis in patients with multiple sclerosis in clinical trials of fingolimod: incidence, prevalence, and impact on disease course. Ophthalmology. 2019;126(3):438–444. doi:10.1016/j.ophtha.2018.10.013.
   PubMed Web of Science ®Google Scholar
• Chaput F, Amer R, Baglivo E, et al. Intraocular T-cell lymphoma: clinical presentation, diagnosis, treatment, and outcome. Ocul Immunol Inflamm. 2017;25(5):639–648.doi:10.3109/09273948.2016.1139733.
   PubMed Web of Science ®Google Scholar
• De Parisot A, Kodjikian L, Errera M-H, et al. Randomized controlled trial evaluating a standardized strategy for uveitis etiologic diagnosis (ULISSE). Am J Ophthalmol. 2017;178:176–185. doi:10.1016/j.ajo.2017.03.029.
   PubMed Web of Science ®Google Scholar
• Grumet P, Kodjikian L, De Parisot A, et al. Contribution of diagnostic tests for the etiological assessment of uveitis, data from the ULISSE study (Uveitis: clinical and medicoeconomic evaluation of a standardized strategy of the etiological diagnosis). Autoimmun Rev. 2018;17(4):331–343.doi:10.1016/j.autrev.2017.10.018.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Dechartres A, Chapron T, et al. Relevance of diagnostic investigations in patients with uveitis: retrospective cohort study on 300 patients. Autoimmun Rev. 2017;16(5):504–511.doi:10.1016/j.autrev.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Abad S, Meyssonier V, Allali J, et al. Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients. Arthritis Rheum. 2004;51(6):974–982.doi:10.1002/art.20839.
   PubMedGoogle Scholar
• Herbort CP, Rao NA, Mochizuki M. members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160–169. doi:10.1080/09273940902818861.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behçet’s disease. International study group for Behçet’s Disease. Lancet. 1990;335(8697): 1078–1080.
   PubMed Web of Science ®Google Scholar
• Yang P, Zhong Y, Du L, et al. Development and evaluation of diagnostic criteria for Vogt-Koyanagi-Harada Disease. JAMA Ophthalmol. 2018;136(9):1025–1031.doi:10.1001/jamaophthalmol.2018.2664.
   PubMed Web of Science ®Google Scholar
• Paule R, Denis L, Chapuis N, et al. Lymphocyte Immunophenotyping and CD4/CD8 ratio in cerebrospinal fluid for the diagnosis of sarcoidosis-related uveitis. Ocul Immunol Inflamm. Published online October 31 2019;1-9. doi:10.1080/09273948.2019.1678647.
   Google Scholar
• Miyanaga M, Kawaguchi T, Shimizu K, Miyata K, Mochizuki M. Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27(2–3):183–188. doi:10.1007/s10792-007-9076-3.
   PubMedGoogle Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192.doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar